Fundz

Nucleus RadioPharma Appoints Former McKesson, Novo Nordisk Executive Kathy Spencer-Pike as Chief Commercial Officer to Drive Business Growth

PRIVATEDec 14, 2023

Position

Chief Commercial Officer

Company

Nucleus RadioPharma

Kathy Spencer-Pike
spencerpike@nucleusrad.com
DavidsonManufacturingBiotechnologyHealth Carepharmaceuticals

Description

Nucleus RadioPharma, a fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, announced the appointment of Kathy Spencer-Pike as Chief Commercial Officer. As a seasoned veteran with decades of commercial experience at McKesson, Novo Nordisk, Sanofi and Pfizer, Spencer-Pike will be responsible for accelerating the growth of the startup following its oversubscribed $56M Series A in October.

Who to call at Nucleus RadioPharma, and when

A new leader at Nucleus RadioPharma brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Nucleus RadioPharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Nucleus RadioPharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Nucleus RadioPharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Nucleus RadioPharma

Location

Davidson, North Carolina, United States

About

Nucleus RadioPharma is an innovative CDMO dedicated to the development and manufacturing of targeted radiotherapies. With an emphasis on innovation and quality, Nucleus provides an array of services, from formulation and analytical development to regulatory documentation and drug product manufacturing. Its technology platforms are at the forefront of radiopharmaceutical research, designed to advance new therapies through clinical trials to commercialization.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Nucleus RadioPharma changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Kathy
Likely contact at this company
••••••••@••••••••

See Kathy's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Nucleus RadioPharma's next move

Learn about Strategic plan

Nucleus RadioPharma changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.